Drug transporters: Recent advances concerning BCRP and tyrosine kinase inhibitors

被引：100

作者：

Lemos, C. ^{[1
,2
]}

Jansen, G. ^{[3
]}

Peters, G. J. ^{[1
]}

机构：

[1] Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands

[2] Univ Porto, Fac Med, Dept Biochem U38 FCT, P-4100 Oporto, Portugal

[3] Vrije Univ Amsterdam, Med Ctr, Dept Rheumatol, NL-1081 HV Amsterdam, Netherlands

来源：

BRITISH JOURNAL OF CANCER | 2008年 / 98卷 / 05期

关键词：

BCRP; multidrug resistance; polymorphisms; stem cells; targeted therapy;

D O I：

10.1038/sj.bjc.6604213

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Multidrug resistance is often associated with the (over) expression of drug efflux transporters of the ATP-binding cassette (ABC) protein family. This minireview discusses the role of one selected ABC-transporter family member, the breast cancer resistance protein (BCRP/ABCG2), in the (pre) clinical efficacy of novel experimental anticancer drugs, in particular tyrosine kinase inhibitors.

引用

收藏

页码：857 / 862

页数：6

相关论文

共 38 条

[1]

The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis [J].

Assaraf, Yehuda G. .

DRUG RESISTANCE UPDATES, 2006, 9 (4-5) :227-246

[2]

Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar [J].

Bihorel, Sebastien ;

Camenisch, Gian ;

Lemaire, Michel ;

Scherrmann, Jean-Michel .

PHARMACEUTICAL RESEARCH, 2007, 24 (09) :1720-1728

[3]

Mammalian ABC transporters in health and disease [J].

Borst, P ;

Elferink, RO .

ANNUAL REVIEW OF BIOCHEMISTRY, 2002, 71 :537-592

[4]

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients [J].

Breedveld, P ;

Pluim, D ;

Cipriani, G ;

Wielinga, P ;

van Tellingen, O ;

Schinkel, AH ;

Schellens, JHM .

CANCER RESEARCH, 2005, 65 (07) :2577-2582

[5]

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells [J].

Brendel, C. ;

Scharenberg, C. ;

Dohse, M. ;

Robey, R. W. ;

Bates, S. E. ;

Shukla, S. ;

Ambudkar, S. V. ;

Wang, Y. ;

Wennemuth, G. ;

Burchert, A. ;

Boudriot, U. ;

Neubauer, A. .

LEUKEMIA, 2007, 21 (06) :1267-1275

[6]

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps [J].

Burger, H ;

van Tol, H ;

Brok, M ;

Wiemer, EAC ;

de Bruijn, EA ;

Guetens, G ;

de Boeck, G ;

Sparreboom, A ;

Verweij, J ;

Nooter, K .

CANCER BIOLOGY & THERAPY, 2005, 4 (07) :747-752

[7]

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump [J].

Burger, H ;

van Tol, H ;

Boersma, AWM ;

Brok, M ;

Wiemer, EAC ;

Stoler, G ;

Nooter, K .

BLOOD, 2004, 104 (09) :2940-2942

[8]

Chen ZS, 2003, CANCER RES, V63, P4048

[9]

Pharmacogenetics of ABCG2 and adverse reactions to gefitinib [J].

Cusatis, George ;

Gregorc, Vanesa ;

Li, Jing ;

Spreafico, Anna ;

Ingersoll, Roxann G. ;

Verweij, Jaap ;

Ludovini, Vienna ;

Villa, Eugenio ;

Hidalgo, Manuel ;

Sparreboom, Alex ;

Baker, Sharyn D. .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (23) :1739-1742

[10]

Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins [J].

Deeley, Roger G. ;

Westlake, Christopher ;

Cole, Susan P. C. .

PHYSIOLOGICAL REVIEWS, 2006, 86 (03) :849-899

← 1 2 3 4 →